ABSTRACT
This study was purposed to explore the effect of troxerotin and cerebroproptein hydrolysate injection (TCHI) on platelet aggregation in vitro and thrombosis in vivo. The inhibitory rate of TCHI at different concentrations on platelet aggregation was determined by platelet aggregometer. The relationship between dose and effect was established. The effect of troxerutin and cerebroproptein hydrolysate injection on thrombosis was determined by the carotid thrombosis model of rats. The results showed that the TCHI could inhibit thrombosis and platelet aggregation in a concentration-dependent way. When the concentration of TCHI total nitrogen was 5 µg/ml, the inhibition rate of platelet aggregation reached to the highest value of 28.61 ± 22.07%, which is 2.5 times as much as that with 100 µg/ml aspirin. It is concluded that the TCHI has antiaggregative and antithrombotic activity effects against platelet aggregation and thrombosis.
Subject(s)
Animals , Rabbits , Rats , Hydroxyethylrutoside , Pharmacology , Platelet Aggregation , Protein Hydrolysates , Pharmacology , Rats, Wistar , ThrombosisABSTRACT
OBJECTIVE: The aim of this study was to assess the clinical efficacy, compliance and safety of Ginko biloba--Troxerutin-Heptaminol Hce in the treatment of patients with acute hemorrhoidal attacks in Thailand. MATERIAL AND METHOD: In a prospective clinical study on hospital outpatients, the authors studied the effect of Ginko biloba--Troxerutin-Heptaminol Hce for a week in adults (18-70 years old) with acute hemorrhoidal attacks. RESULT: Twenty-two patients, with a mean age of 41.7 years were included in the study. The male to female ratio was 1 : 1.2. Most patients (77%) had grade 1 and 2 hemorrhoids with an average duration of attacks of 3 days. On intention to treat analysis, bleeding, pain, tenesmus and discharge were significantly improved. Treatment was well accepted and safe. CONCLUSION: In the short-term, Ginko biloba--Troxerutin-Heptaminol Hce is effective, acceptable and safe in the treatment of patients with acute hemorrhoidal attacks.
Subject(s)
Acute Disease , Adolescent , Adult , Aged , Drug Therapy, Combination , Female , Follow-Up Studies , Ginkgo biloba , Hemorrhoids/diagnosis , Heptaminol/therapeutic use , Humans , Hydroxyethylrutoside/analogs & derivatives , Male , Middle Aged , Pain Measurement , Phytotherapy/methods , Prospective Studies , Risk Assessment , Severity of Illness Index , Treatment OutcomeABSTRACT
The safety and efficacy of Trihydroxyethylrutosides (HR) in the treatment of 53 patients with 1st-2nd degree hemorrhoids of pregnancy (16th-34th week) was investigated in a double-blind randomised, placebo controlled trial. The dosage of Trihydroxyethylrutosides was 1 tablet of 300 milligrams twice daily for the first 2 weeks. If the treatment was successful, the treatment was stopped. If the clinical signs or symptoms still persisted, the treatment was continued for another two weeks using the same dosage and re-evaluated at the end of the fourth week after initial treatment. The parameters for efficacy were symptoms (pain, bleeding, exudation and pruritus) and the objective signs on proctoscopy (bleeding, inflammation and dilatation of the hemorrhoidal venous plexus). The study revealed improvement of symptoms in the study group which was better than in the control group after 2 weeks of treatment but the clinical signs were not different. After a further 2 weeks of treatment, the result showed improvement of both clinical signs and symptoms in this study. Only one mild transient side effect was reported in the HR group and there were no drug-related problems in the pregnancies, delivery or the babies.
Subject(s)
Administration, Oral , Adult , Double-Blind Method , Female , Hemorrhoids/drug therapy , Humans , Hydroxyethylrutoside/administration & dosage , Pregnancy , Pregnancy Complications/drug therapy , Statistics, Nonparametric , Treatment OutcomeABSTRACT
To evaluate the effectiveness of medical treatment in patients with aphakic and pseudophakic cystoid macular edema [CME]. A two years prospective study of 25 cases with CME following cataract surgery. Every case underwent full ophthalmological examination and fluorescein fundus angiography. All cases treated by topical non-steroidal anti-inflammatory [Diclofenac 01%] ophthalmic solution 1-2 drops 4 times a day, 10 cases received 0 - [B - hydroxyaethyl] -rutosidea [Venoruton - 300] capsules 1200 mg in two divided oral dose daily for 2 weeks together with the topical diclofenac. Follow-up ranged 6 - 30 months [mean 19 months]. The 25 eyes of 25 patients all unilateral. 21[84.0%] pseudophakic and 4[16.0%] aphakic. Mean duration of CME [10.50 months]. Mean BCVA 0.2. Two groups were identified according to medical treatment, Group A - 15 cases received diclofenac 0.1% alone with 13 [86.7%] improved in a mean period of 8.5 weeks, 2 [13.4%] not improved and 3 [23.1%] with on/off phenomenon. Group B - 10 cases received topical diclofenac 0.1% together with Venoruton 300 capsules 9 [90.0%] improved in a mean 5 weeks, 1 [10.0%] not improved and 1 [11.2%] with on/off phenomenon. Topical non - steroidal anti-inflammatory drugs [Diclofenic 0.1%] ophthalmic solution proved to be beneficial in the prevention and treatment of chronic aphakic and pseudopahkic cystoid macular edema. Oral O - [B - hydroxyaethyl] - rutosidea [Venoruton 300] capsules was beneficial in the present study in augmenting the action of topical diclofenac by shortening the duration of recovery and lowering the rate of recurrence [on/off] phenomenon, but needs further studies